AR021981A1 - PHARMACEUTICAL COMPOSITION FOR AN ORAL ROUTE ADMINISTRATION TO AVOID THE DEVIATION OF USE THROUGH A THIRD PARTY - Google Patents

PHARMACEUTICAL COMPOSITION FOR AN ORAL ROUTE ADMINISTRATION TO AVOID THE DEVIATION OF USE THROUGH A THIRD PARTY

Info

Publication number
AR021981A1
AR021981A1 ARP990106668A ARP990106668A AR021981A1 AR 021981 A1 AR021981 A1 AR 021981A1 AR P990106668 A ARP990106668 A AR P990106668A AR P990106668 A ARP990106668 A AR P990106668A AR 021981 A1 AR021981 A1 AR 021981A1
Authority
AR
Argentina
Prior art keywords
party
deviation
pharmaceutical composition
avoid
oral route
Prior art date
Application number
ARP990106668A
Other languages
Spanish (es)
Original Assignee
Addario Ezio Nicola D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addario Ezio Nicola D filed Critical Addario Ezio Nicola D
Publication of AR021981A1 publication Critical patent/AR021981A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion farmacéutica para administracion por vía oral destinada a evitar la desviacion de uso en detrimento de un tercero.A pharmaceutical composition for oral administration aimed at preventing the deviation of use to the detriment of a third party.

ARP990106668A 1998-12-23 1999-12-22 PHARMACEUTICAL COMPOSITION FOR AN ORAL ROUTE ADMINISTRATION TO AVOID THE DEVIATION OF USE THROUGH A THIRD PARTY AR021981A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9816309A FR2787715B1 (en) 1998-12-23 1998-12-23 PHARMACEUTICAL COMPOSITION COMPRISING A HYPNOTIC COMPOUND OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS

Publications (1)

Publication Number Publication Date
AR021981A1 true AR021981A1 (en) 2002-09-04

Family

ID=9534386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106668A AR021981A1 (en) 1998-12-23 1999-12-22 PHARMACEUTICAL COMPOSITION FOR AN ORAL ROUTE ADMINISTRATION TO AVOID THE DEVIATION OF USE THROUGH A THIRD PARTY

Country Status (6)

Country Link
EP (1) EP1140011A1 (en)
AR (1) AR021981A1 (en)
AU (1) AU1663900A (en)
CO (1) CO5150153A1 (en)
FR (1) FR2787715B1 (en)
WO (1) WO2000038649A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1299104B1 (en) 2000-02-08 2009-05-13 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
DE60238756D1 (en) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc OPIOID CONTAINING ARZNEIFORM AGAINST MISUSE
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE60219478T2 (en) 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. ORAL GIVEN OF 6-HYDROXY-OXYMORPHONE AS ANALGETIC
CA2457361C (en) 2001-08-06 2008-11-04 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
FR2829933B3 (en) * 2001-09-21 2004-03-12 Ellipse Pharmaceuticals PROCESS FOR THE MANUFACTURE OF AN ORAL ADMINISTRATIVE PHARMACEUTICAL PRODUCT WITH DECEPTING AGENTS IN PARTICULAR OF TASTE AND PRODUCT OBTAINED
EP2425821B1 (en) 2002-04-05 2017-05-10 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
EP2422773A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
KR20150038745A (en) * 2004-02-17 2015-04-08 트랜스셉트 파마슈티칼스, 인코포레이티드 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
WO2006002836A1 (en) * 2004-07-01 2006-01-12 Losan Pharma Gmbh Effervescent compositions of sleeping drugs
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
KR20140079441A (en) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 Pharmaceutical compositions
FR2904225B1 (en) * 2006-07-28 2010-08-13 Bouchara Recordati PHARMACEUTICAL COMPOSITIONS OF ACTIVE SUBSTANCES DIFFICULTY OF THE ROUTE OF ADMINISTRATION TO WHICH THEY ARE INTENDED
CA2696341C (en) 2007-08-13 2016-05-17 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
TW201006473A (en) * 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
JP5886632B2 (en) 2009-03-10 2016-03-16 ユーロ−セルティーク エス．エイ． Immediate release pharmaceutical composition comprising oxycodone and naloxone
FR2949062B1 (en) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
FR2962331B1 (en) * 2010-07-06 2020-04-24 Ethypharm PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION, METHOD USING THE SAME
FR2962550B1 (en) * 2010-07-06 2013-06-14 Ethypharm Sa METHOD FOR CONTROLLING CHEMICAL SUBMISSION, USE OF COLORING AGENT FOR COMBATING CHEMICAL SUBMISSION AND PHARMACEUTICAL COMPOSITION FOR THE IMPLEMENTATION OF THE METHOD
FR2968995B1 (en) 2010-12-16 2013-03-22 Sanofi Aventis PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION TO PREVENT MEASUREMENT
FR2968992B1 (en) * 2010-12-16 2013-02-08 Sanofi Aventis ORODISPERSIBLE PHARMACEUTICAL TABLET BASED ON ZOLPIDEM
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR20160034352A (en) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
GB201316857D0 (en) * 2013-09-23 2013-11-06 Buckley Howard Composition for the oral delivery of compounds
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
JP2017531026A (en) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Sustained release abuse deterrent liquid filler form
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US20220202742A1 (en) * 2019-05-07 2022-06-30 Clexio Biosciences Ltd. Dosage forms for preventing drug-facilitated assault
PT3799864T (en) * 2019-10-02 2023-05-25 Intas Pharmaceuticals Ltd Essentially sodium-free effervescent solid pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097155T3 (en) * 1989-10-02 1997-04-01 Cima Labs Inc EFFERVESCENT DOSAGE FORM AND METHOD OF ADMINISTRATION.
GB8926612D0 (en) * 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
IT1264696B1 (en) * 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies

Also Published As

Publication number Publication date
FR2787715A1 (en) 2000-06-30
WO2000038649A1 (en) 2000-07-06
CO5150153A1 (en) 2002-04-29
AU1663900A (en) 2000-07-31
FR2787715B1 (en) 2002-05-10
EP1140011A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
AR021981A1 (en) PHARMACEUTICAL COMPOSITION FOR AN ORAL ROUTE ADMINISTRATION TO AVOID THE DEVIATION OF USE THROUGH A THIRD PARTY
TR199901077A2 (en) �spen�iyari form�lasyonlar.
CY1108532T1 (en) UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
UY28001A1 (en) CONDENSED AZOL-PYRIMIDINE DERIVATIVES
BR9912975A (en) Compound and compositions for release of active agents, method for obtaining and using them
DE69925133D1 (en) PYRROLOBENZODIAZEPINE
BR9810495A (en) Pharmaceutical composition
DE69934831D1 (en) MULTIPLEXES, MEDICAMENT DELIVERY SUITABLE FOR ORAL ADMINISTRATION
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
BG66093B1 (en) Controlled release compositions comprising nimesulide
DK1121127T3 (en) Oral pharmaceutical compositions containing buprenorphine
DK1185253T3 (en) Oral preparation for administration of a solid combination of tramadol and diclofenac
DK1097173T3 (en) Use of IL-2 peptides and derivatives thereof as therapeutic agents
AR021934A1 (en) COMPOSITION OF ORAL ADMINISTRATION WITH CONTROLLED RELEASE OF AT LEAST ONE ANALGESIC
DK1104289T3 (en) New oral formulations for 5-HT 4 agonists or antagonists
ATE321538T1 (en) ORAL PHARMACEUTICAL FORM FOR PYRIDINE-2-YLMETHYLSULFINYL-1H-BENZIMIDAZOLE
BR0112847A (en) Use of a solid dosage form
HN2001000235A (en) DERIVATIVES BRIDGES OF PIPERAZINA
BR0317623A (en) Escitalopram, pharmaceutical composition, and use of escitalopram hydrobromide
DE60128100D1 (en) ANALGICAL DRUG
ATE353224T1 (en) DISPENSING DEVICE FOR A COMPOSITION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE
BR9814495A (en) Compound, process to prepare it, use of it, pharmaceutical composition, and, process
EA200501565A1 (en) INTENDED FOR ORAL ADMINISTRATION MEDICINE FORM FOR PROTONE PUMP ANTAGONISTS
UY26224A1 (en) PHARMACEUTICAL COMPLEX LAW 17164 ART. 127
AR043016A2 (en) AN ELTIRIPTAN ANTIMIGRANIC COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING IT